Ocular hypotensive lipids
CA 2400323 A1 · Owner: Madhu, Cherukury · Inventors: Krauss, Achim H. P.; Andrews, Steven W.; Usansky, Helen H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (1), where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF2.alpha. 1-ethanolamide, having the formula (I) was discovered to be present in mammalian tissue as a naturally occuring substance was synthesized , in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye but not acting through the FP , receptor through which many ocular hypotensive prostaglandins act.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 5, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.